Can I read Famciclovir/ruxolitinib/valaciclovir: Hypertrophic herpes simplex virus-2 infection and acquired drug resistance: case report on EtoBox?

Famciclovir/ruxolitinib/valaciclovir: Hypertrophic herpes simplex virus-2 infection and acquired drug resistance: case report is a Medicine article available to read on EtoBox.

What is Famciclovir/ruxolitinib/valaciclovir: Hypertrophic herpes simplex virus-2 infection and acquired drug resistance: case report about?

Famciclovir/ruxolitinib/valaciclovir Hypertrophic herpes simplex virus-2 infection and acquired drug resistance: case report An approximately 77-year-old man developed hypertrophic herpes simplex virus-2 (HSV-2) infection during immunosuppressive treatment with ruxolitinib for myelofibrosis. Additionally, he acquired resistance to valaciclovir and famciclovir while being treated for hypertrophic HSV-2 infection [not all routes, dosages and outcomes stated; duration of treatments to reactions onsets not stated].The man was referred to infectious diseases clinic at 80 years of age with a subacute, progressive mass over the left forehead. He had been receiving ruxolitinib for myelofibrosis, metformin for type-2 diabetes mellitus and simvastatin for dyslipidaemia. His regular medicines also included rabeprazole. Three years prior to the presentation, at approximately 77 years of age, he had developed an erythematous, crusting rash over outer side of his left ear. Otitis externa was presumed.The man received 14 courses of empiric unspecified antibacterial therapy with no improvement. Subsequently, a swab was taken from the lesion, which was positive for HSV-2 on PCR testing. He then rec

Who reads Famciclovir/ruxolitinib/valaciclovir: Hypertrophic herpes simplex virus-2 infection and acquired drug resistance: case report?

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)